Observational Study
Copyright ©The Author(s) 2017.
World J Gastroenterol. Sep 14, 2017; 23(34): 6294-6305
Published online Sep 14, 2017. doi: 10.3748/wjg.v23.i34.6294
Table 4 Number of Crohn’s disease patients and the use of biologicals
CountryEstimated number of CD patients/sourceNumber of patients on biologicals1/sourcePatients on biologicals per 100000 population (calculated)Patients on biologicals per 1000 patients (calculated)
Cz8768Rencz et al[3], 2015 (based on estimation)990Rencz et al[3], 20159.4112.9
Fr72522Kirchgesner et al[28], 2017 (administrative database)22671Estimation based on Kirchgesner et al[28], 201734.0312.6
D180000Estimate by the collaborating expert based on CD incidence and prevalence in two regional cohort studies from the 90ties.27000Estimation (based on the estimated % of patients on biologicals and the total number of CD patients)32.9150.0
Hu9775Rencz et al[3], 2015 (based on epidemiology study)1870Rencz et al[3], 201519.0191.3
Lv1695Rencz et al[3], 2015 (based on estimation)3Rencz et al[3], 20150.21.8
Pl32049Rencz et al[3], 2015 (based on estimation)888Rencz et al[3], 20152.327.7
Ro11000Estimate for 2016 by the collaborating expert based on National database including 13 IBD centers253Rencz et al[3], 20151.323.0
Sk3687Rencz et al[3], 2015 (epidemiology study)690Rencz et al[3], 201512.7187.1
Es60000Arin Letamendia et al[29], 2008 (prospective, population-based study)15000Estimation (based on the estimated % of patients on biologicals from the ENEIDA database2 and the total number of CD patients)32.3250.0
Se34318SWIBREG3 combined with the Swedish National Patient Register5270SWIBREG3 combined with The Prescribed Drug Register53.5153.6